Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SECOMBIT: Sequencing of Ipilimumab/Nivolumab and Encorafenib/Binimetinib in Melanoma
NCT02631447Phase 2Completed
- Start
- Nov 2016
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of encorafenib, binimetinib in melanoma. Started Nov 2016; status: completed.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02631447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02631447.